View Post

DelMar Pharmaceuticals Achieves Halfway Enrollment Point for Phase 2 Clinical Trial of VAL-083 in Newly Diagnosed MGMT-unmethylated GBM

In Clinical Trials by Barbara Jacoby

From: financialbuzz.com DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that its Phase 2 study testing VAL-083 in patients with newly diagnosed glioblastoma multiforme (GBM) has achieved its halfway enrollment point. This trial, targeted to enroll up to thirty patients, is a single-arm, open-label study …

View Post

The FDA’s Oncology Center of Excellence — Quantifying the Patient Experience

In In The News by Barbara Jacoby

By: Paul G. Kluetz, M.D. From: fda.gov Cancer therapies are typically evaluated based on their ability to control the growth of a tumor or extend life. Tumor response and survival data are strong trial endpoints that remain the mainstay of regulatory review, but cancer patients have other meaningful concerns as well, such as coping with treatment-related side effects that can …

View Post

Vital step in stem cell growth revealed

In In The News by Barbara Jacoby

Salk scientists’ finding could aid regenerative and cancer therapies LA JOLLA—Stem cells, which have the potential to turn into any kind of cell, offer the tantalizing possibility of generating new tissues for organ replacements, stroke victims and patients of many other diseases. Now, scientists at the Salk Institute have uncovered details about stem cell growth that could help improve regenerative …

Nontoxic cancer therapy proves effective against metastatic cancer

In In The News by Barbara Jacoby

A combination of nontoxic dietary and hyperbaric oxygen therapies effectively increased survival time in a mouse model of aggressive metastatic cancer, a research team from the Hyperbaric Biomedical Research Laboratory at the University of South Florida has found. The study, “The Ketogenic Diet and Hyperbaric Oxygen Therapy Prolong Survival in Mice with Systemic Metastatic Cancer,” was published online today in …

Breakthrough in breast cancer surgery without disfigurement

In In The News by Barbara Jacoby

Serious tissue damage and disfigurement are a major fallout of most cancer therapies, but the one for breast cancer in particular has life-altering impact on women. Chicago-based Ananda Chakrabarty, a world-renowned pioneering biotech scientist, and Washington-based Susan Finston, a veteran of the biotech industry, together believe they are potentially close to resolving this major medical challenge. Finston passionately talks about …